MedPath

The impact of serum testosterone level as prognosis factor for CRPC with enzalutamide or Abraterone

Not Applicable
Recruiting
Conditions
Castration resistant prostate cancer :CRPC
Registration Number
JPRN-UMIN000019493
Lead Sponsor
Aichi cancer center hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Male
Target Recruitment
42
Inclusion Criteria

Not provided

Exclusion Criteria

without informed consent to entry in this study

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath